
## **BRAF** Antibody


Rabbit Polyclona Antigen Affinity	- •	Protein ID	NP_004324.2			
5	4301-695 4301-695		GenelD	673		BETHYL LABORATORIES, INC
APPLICATIONS	W	/B, IP, IHC				Developer consistent of the local Developed of the
SPECIES REACTIVITY		Human				
PRESUMED REACTIVITY		Based on 100% sequence identity, this antibody is predicted to react with Mouse				
AMOUNT		100 µl				
CONCENTRATION		200 µg/ml				
STORAGE/SHELF LIFE		2 - 8° C / 1 year from date of receipt				
PHYSICAL STATE		Liquid				
BUFFER		Tris-buffered Saline containing 0.1% BSA and 0.09% Sodium Azide				
ISOTYPE		IgG				
ORIGIN		USA				
PRODUCTION PROCEDURES		Antibody was affinity purified using an epitope specific to BRAF immobilized on solid support.				
TROCEDORES		The epitope recognized by A301–695A maps to a region between residue 25 and 75 of human v- raf murine sarcoma viral oncogene homolog B1 using the numbering given in entry NP_004324.2 (GeneID 673).				
		Immunoglobulin concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG.				
APPLICATIONS		Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.				
		Vestern Blot	1:2	2,000 - 1:10,000		
	Ir	mmunoprecipi	tation 2 -	- 5 µg/mg lysate		
	Ir	mmunohistoch	/	200 – 1:1,000. Epitope commended for FFPE tis		buffer pH 6.0 is
APPLICATION NOTES		Western blot of immunoprecipitates performed using Normal Pig Serum (Cat. No. S100–020), Goat anti–Rabbit Light Chain HRP Conjugate (Cat. No. A120–113P) and 4–8% SDS–PAGE (link to IP–western blot protocol in Additional Info section below).				
IHC HUMAN CONTROLS ADDITIONAL INFO		Western blot of lysates performed using standard western blot reagents and 4–8% SDS-PAGE. Breast Carcinoma, Prostate Carcinoma				
		https://www.bethyl.com/product/A301-695A Use the link above to view SDS, a current list of citations, and other product specific information. IP-western blot protocol: https://www.bethyl.com/content/protocol_IP_WB				

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc. Eric McIntush, PhD | Chief Scientific Officer Date: June 21, 2019

For in vitro laboratory use only. Not for any clinical, therapeutic or diagnostic use in humans or animals. Not for human or animal consumption. This product may not be resold or modified for resale without the prior written approval of Bethyl Laboratories, Inc. The information provided in this data sheet is believed to be correct but does not purport to be all-inclusive and is intended to be used as a guide. Bethyl Laboratories, Inc. shall not be liable or responsible in any way for use of either this information or the material supplied. Disposal of hazardous material may be subject to federal, state or local laws or regulations.



Detection of human BRAF by western blot and immunoprecipitation. *Samples:* Whole cell lysate from HeLa (5, 15 and 50 µg for WB; 1 mg for IP, 20% of IP loaded) and HEK293T (T; 50 µg) cells. *Antibodies:* Affinity purified rabbit anti-BRAF antibody A301-695A used for WB at 0.04 µg/ml (A) and 1 µg/ml (B) and used for IP at 3 µg/mg lysate. BRAF was also immunoprecipitated by rabbit anti-BRAF antibody BL6525, which recognizes a downstream epitope. *Detection:* Chemiluminescence with exposure times of 3 minutes (A) and 10 seconds (B).



**Detection of human BRAF by immunohistochemistry.** *Sample:* FFPE section of human prostate carcinoma. *Antibody:* Affinity purified rabbit anti-BRAF (Cat. No. A301-695A) used at a dilution of 1:200 (1µg/ml). *Detection:* DAB